» Articles » PMID: 37363044

Theoretical Aspects of Interaction of the Anticancer Drug Cytarabine with Human Serum Albumin

Overview
Journal Struct Chem
Date 2023 Jun 26
PMID 37363044
Authors
Affiliations
Soon will be listed here.
Abstract

Despite diagnostic and therapeutic methods, cancer is a major cause of death worldwide. Since anticancer drugs affect both normal and cancer cells, targeted drug delivery systems can play a key role in reducing the destructive effects of anticancer drugs on normal cells. In this regard, the use of stimulus-sensitive polymers has increased in recent years. This study has attempted to investigate interaction of the anticancer drug cytarabine with a stimuli-sensitive polymer, human serum albumin (HSA), one of the most abundant protein in blood plasma, via computational methods at both body temperature and tumor temperature. For this purpose, molecular docking was performed using Molegro virtual Docker software to select the best ligand in terms of binding energy to simulate molecular dynamics. Then, molecular dynamics simulation was performed on human serum albumin with code (1Ao6) and cytarabine with code (AR3), using Gromacs software and the results were presented in the graphs. The simulations were performed at 310 K (normal cell temperature) and 313 K (cancer cell temperature) in 100 ns. Results showed drug release occurred at a temperature of 313 K. These findings demonstrated the sensitivity of human serum albumin to temperature.

Citing Articles

Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.

Wang Z, Wang X, Xu W, Li Y, Lai R, Qiu X Pharmaceutics. 2023; 15(11).

PMID: 38004601 PMC: 10674763. DOI: 10.3390/pharmaceutics15112623.

References
1.
Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D . Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003; 257(1-2):169-80. DOI: 10.1016/s0378-5173(03)00134-0. View

2.
Ding C, Tong L, Feng J, Fu J . Recent Advances in Stimuli-Responsive Release Function Drug Delivery Systems for Tumor Treatment. Molecules. 2016; 21(12). PMC: 6273707. DOI: 10.3390/molecules21121715. View

3.
Pires D, Blundell T, Ascher D . pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9):4066-72. PMC: 4434528. DOI: 10.1021/acs.jmedchem.5b00104. View

4.
Bharali D, Mousa S . Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther. 2010; 128(2):324-35. DOI: 10.1016/j.pharmthera.2010.07.007. View

5.
Karwasra R, Ahmad S, Bano N, Qazi S, Raza K, Singh S . Macrophage-Targeted Punicalagin Nanoengineering to Alleviate Methotrexate-Induced Neutropenia: A Molecular Docking, DFT, and MD Simulation Analysis. Molecules. 2022; 27(18). PMC: 9505199. DOI: 10.3390/molecules27186034. View